Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05372419 · ClinicalTrials.gov registry record · Phase 3
A Study of (LY3650150) Lebrikizumab to Assess the Safety and Efficacy of Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis and Skin of Color
A Phase 3 study of Atopic Dermatitis, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 3
- Development phase
- 90
- Enrollment target
- 20
- Study locations
NCT05372419 is a Phase 3 study of Atopic Dermatitis that has completed, run by Eli Lilly and Company. The registered enrollment target is 90 participants, below the 609-participant average among 150 other Atopic Dermatitis trials with a reported enrollment target (85% lower). The trial reports 20 study locations across 5 states.
The verdict
NCT05372419, a Phase 3 study of Atopic Dermatitis, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 90 participants
- Enrollment target
- 20
- Study locations
Study Summary
The main purpose of this study is to determine the safety and efficacy lebrikizumab in adolescent and adult participants with moderate-to-severe atopic dermatitis (AD) and skin of color.
Conditions Studied
Interventions
- DRUG Lebrikizumab
Study Locations (20)
California
- First OC Dermatology - Fountain Valley
- Center For Dermatology Clinical Research, Inc. - Fremont
- Axon Clinical Research - Inglewood
- Avance Clinical Trials Inc - Laguna Niguel
- Dermatology Research Associates - Los Angeles
- Wallace Medical Group, Inc. - Los Angeles
- Cura Clinical Research - Palmdale
- University of California Davis (UC Davis) Comprehensive Cancer Center - Sacramento
- Clinical Science Institute - Santa Monica
- Cura Clinical Research - Sherman Oaks
Florida
- Encore Medical Research of Boynton Beach - Boynton Beach
- Skin Care Research, Inc - Hollywood
- Solutions Through Advanced Research - Jacksonville
- Miami Dermatology and Laser Research - Miami
- Savin Medical Group, LLC - Miami Lakes
- PureSkin Dermatology - Orlando
Georgia
- Skin Care Physicians of Georgia - Macon
- Advanced Medical Research - Sandy Springs
Alabama
- Total Skin and Beauty Dermatology Center, PC - Birmingham
Connecticut
- UConn Health - Farmington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2023-01-12 |
| Est. Completion | 2025-02-17 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05372419
The ClinicalTrials.gov registry entry for NCT05372419 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 90 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 609-participant average among 150 other Atopic Dermatitis trials with a reported enrollment target (85% lower). The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Atopic Dermatitis appearing as the primary indexed condition, and to 1 intervention - of which Lebrikizumab is the first listed.
NCT05372419 reports 20 study locations spanning 5 distinct geographic areas - top geographies include California, Florida, Georgia.
Frequently Asked Questions
What is clinical trial NCT05372419 about?
NCT05372419 is a clinical study titled "A Study of (LY3650150) Lebrikizumab to Assess the Safety and Efficacy of Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis and Skin of Color". The main purpose of this study is to determine the safety and efficacy lebrikizumab in adolescent and adult participants with moderate-to-severe atopic dermatitis (AD) and skin of color.
What is the current status of trial NCT05372419?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 90 participants. The study started on 2023-01-12. Estimated completion is 2025-02-17.
What conditions does trial NCT05372419 study?
This clinical trial studies the following conditions: Atopic Dermatitis.
What interventions are being tested in trial NCT05372419?
The interventions under investigation include: Lebrikizumab (DRUG).
Who is sponsoring clinical trial NCT05372419?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05372419 being conducted?
This trial has 20 study locations across Alabama, California, Connecticut, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Atopic Dermatitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Investigate Safety and Efficacy of Tapinarof Cream, 1% in Participants Ages 3 Months to < 24 Months With Atopic Dermatitis
RECRUITING · Phase 3
-
A Long-term Study of the Medicine Called Abrocitinib in Children Aged 2 Years and Older With Moderate to Severe Eczema
RECRUITING · Phase 3
-
A Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Children and Infants With Moderate-to-severe Atopic Dermatitis
RECRUITING · Phase 3
-
A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis
RECRUITING · Phase 3
-
A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children and Adolescents (6 to <18 Years Old) With Moderate Atopic Dermatitis
RECRUITING · Phase 3
-
A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.